GSK's Six-Monthly Asthma Biologic Could Reshape Treatment Standards From London to Lagos
GlaxoSmithKline is targeting a 2027 global launch for depemokimab, an ultra-long-acting biologic that could require just two injections per year — a potential game-changer for the millions of severe asthma patients worldwide who struggle with monthly treatment regimens. The drug enters a $164 billion market where patient adherence is a universal challenge, particularly acute in lower-resource healthcare systems. If validated, it could shift prescribing patterns across developed and emerging mark
ViaNews Editorial Team•